Navigation Links
FDA Renews Heart-Risk Warning for Antibiotic
Date:3/12/2013

By Steven Reinberg
HealthDay Reporter

TUESDAY, March 12 (HealthDay News) -- U.S. health officials reiterated Tuesday that the widely prescribed antibiotic azithromycin (Zithromax, Zmax) may slightly raise the risk of death in patients with heart problems.

Specifically, the drug and others in its class called macrolides can cause abnormal changes in the electrical activity of the heart that may lead to a potentially fatal irregular heart rhythm, the U.S. Food and Drug Administration said.

Responding to the FDA warning, Dr. Gregg Fonarow, director of the Ahmanson-UCLA Cardiomyopathy Center, said, "It is important for doctors to be fully aware of the potential risk of fatal heart rhythms that can result from the administration of certain medications, particularly in patients with certain risk factors."

Those at highest risk for this problem are people with known risk factors, such as existing heart problems, particularly what is known as QT prolongation; low levels of potassium or magnesium; a slower than normal heartbeat; or taking certain drugs to treat abnormal heart rhythms, the FDA said.

The risks associated with azithromycin appear to be small in absolute terms, and other antibiotics also have the potential for QT prolongation and what's known as torsades de pointes, which is an abnormally fast heartbeat that can lead to cardiac arrest, Fonarow said.

The FDA's action is based on its review of a study published last May in the New England Journal of Medicine that found this problem with azithromycin. In that study, researchers calculated the absolute risk at 47 cardiovascular deaths for every 1 million prescriptions for azithromycin.

At that time, the FDA said patients taking the drug should be aware of the potential for heart problems. It also said it would review the study.

The agency's announcement Tuesday was also based on a study done by one maker of the drug that looked at the potential for irregular heart rhythms associated with azithromycin.

Based on these studies, the FDA said, the drug's label has been updated to strengthen the warning of heart problems in some patients. The agency is asking doctors to consider the potentially fatal heart rhythms when prescribing azithromycin, especially to high-risk patients.

Azithromycin isn't the only antibiotic linked to potentially fatal heart problems. Fluoroquinolones, which are a different type of antibiotics, also "have the potential for QT prolongation or other significant side effects that should be considered when choosing an antibacterial drug," the FDA said in a news release.

More information

For more on azithromycin, visit the U.S. National Library of Medicine.

SOURCES: Gregg Fonarow, M.D., director, Ahmanson-UCLA Cardiomyopathy Center and co-director of the UCLA Preventative Cardiology Program, University of California, Los Angeles; U.S. Food and Drug Administration, news release, March 12, 2013


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Marietta Dentist Kirk Kimmerling DDS Renews Pledge to Calvary Children’s Home
2. Northbound Treatment Services Renews Successful Holistic Approach
3. Federal government renews contract for collecting and maintaining national stem cell transplantation database
4. Law Firm Issues Biomet Hip Infographic Warning Consumers About the Dangers of Biomet Hip Implants
5. Specific warning signs of complications in colorectal surgical patients released
6. FDA Issues Another Warning on Fake Version of Cancer Drug Avastin
7. Graphic warnings on cigarettes effective across demographic groups
8. DrugRisk Announces New Pradaxa Health Warning From Australia
9. DrugRisk Adds Latest Health Warnings and Lawsuit Updates for Yaz
10. Fake Drugs Entering the U.S.: Lawyers at Console & Hollawell Highlight Federal Warnings About Counterfeit Medications
11. Warning Claim on Alleged Defective Wright Hip Implant Lawsuit Dismissed: AttorneyOne Informs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... (PRWEB) , ... December 09, 2016 , ... ... whiteboard display solutions, proudly announced today that a new solution for Emergency Departments ... fit in the tight space in Emergency Department examination rooms, and with a ...
(Date:12/8/2016)... Cambridge, MA (PRWEB) , ... December 08, 2016 ... ... the Workers Compensation Research Institute (WCRI) officially opened registration today for its ... Place Hotel in Boston, MA . , The theme of the conference is ...
(Date:12/8/2016)... ... December 08, 2016 , ... CURE Media Group, the nation’s leading digital ... aligned with Upstage Lung Cancer in efforts to combat lung cancer, announced CURE Media ... Jr said, “CURE Media Group is honored to team up with Upstage Lung Cancer ...
(Date:12/8/2016)... (PRWEB) , ... December 08, ... ... Presence Suite 10.2 version gives development continuity to its innovative Unified Instance ... channels management capacity. In addition, this new version optimizes the unattended auto-dialing ...
(Date:12/8/2016)... ... December 08, 2016 , ... Today’s patients are encouraged ... in mind, SIGVARIS has created a new line of anti-embolism stockings to help ... provide the benefits of graduated compression when transitioning from recovery to early rehabilitation. ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... of the market in 2016 and is expected to ... attributed to a large number of surgical procedures that ... largest share in the patient temperature management market.) Patient ... reducing loss of blood during surgeries, lowering the risks ...
(Date:12/8/2016)... Research and Markets has announced the addition ... Adhesion Type, Application, Usability - Forecast to 2025" report to ... , , ... poised to grow at a CAGR of around 3.2% from 2015 ... witnessing include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research ...
(Date:12/8/2016)... 2016  Valeant Pharmaceuticals International, Inc. (NYSE: ... announced positive results from a Phase 3, multicenter ... safety and efficacy of IDP-118 (halobetasol propionate and ... Within the Phase 3 study ... psoriasis, IDP-118 showed statistical significance to vehicle with ...
Breaking Medicine Technology: